Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Dominik Vahrenhorst
CureVac AG
Tübingen
Germany
Contact
CureVac AG
Email
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
133
TOTAL CITATIONS
1
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study
Number of pages: 33
Posted: 30 Dec 2021
Xavier Sáez-Llorens
,
Claudio F. Lanata
,
Elaine Aranguren
,
Carlos R. Celis
,
Rubelio Cornejo
,
Rodrigo DeAntonio
,
Lucie Ecker
,
Diegi Garrido
,
Ana I. Gil
,
Marina Gonzales
,
Morgan Hess-Holtz
,
Geert Leroux-Roels
,
Helga Junker
,
Sarah-Katharina Kays
,
Sven D. Koch
,
Sandra Lazzaro
,
Philipp Mann
,
Gianluca Quintini
,
Barkha Srivastava
, Dominik Vahrenhorst,
Philipp von Eisenhart-Rothe
,
Olaf-Oliver Wolz
and
Lidia Oostvogels
Cevaxin, Instituto de Investigación Nutricional, Cevaxin, Instituto de Investigación Nutricional, Instituto de Investigación Nutricional, Cevaxin, Instituto de Investigación Nutricional, Cevaxin, Instituto de Investigación Nutricional, CureVac AG, Cevaxin, Ghent University - Ghent University Hospital, CureVac AG, CureVac AG, CureVac AG, CureVac AG, CureVac AG, CureVac AG, CureVac AG, CureVac AG, CureVac AG, CureVac AG and CureVac AG
Downloads
133
(547,695)
Citation
1
View PDF
Download
Abstract:
COVID-19, vaccine, mRNA, clinical trial
Feedback
